Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Clinical trial NCT02404051 · UNKNOWN

Trial details

NCT number: NCT02404051
Sponsor: Consorzio Oncotech
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Breast Cancer Breast Cancer Hormone Receptor Positive Tumor Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Locally Advanced Malignant Neoplasm

Start date: 2015-12-01
Primary completion: 2018-01-01
Enrollment: 745

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.